The Lynx Group

ASCO 2017 – Multiple Myeloma

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.
Read Article

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).
Read Article


The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.
Read Article


Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.
Read Article

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article

Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article


Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: